Based on the Novocure Ltd stock forecast from 4 analysts, the average analyst target price for Novocure Ltd is USD 34.36 over the next 12 months. Novocure Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Novocure Ltd is Bearish, which is based on 1 positive signals and 9 negative signals. At the last closing, Novocure Ltd’s stock price was USD 16.49. Novocure Ltd’s stock price has changed by -12.57% over the past week, -14.38% over the past month and +20.01% over the last year.
No recent analyst target price found for Novocure Ltd
No recent average analyst rating found for Novocure Ltd
Company Overview Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Read Less
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company...Read More
Frequently Asked Questions About Novocure Ltd (NVCR) Stock
Based on ratings from 4 analysts Novocure Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NVCR's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for NVCR is USD 34.36 over the next 12 months. The maximum analyst target price is USD 46 while the minimum anlayst target price is USD 28.
NVCR stock's Price/Earning ratio is 1,480.87.
Our analysis grades NVCR stock's Price / Earning ratio at F. This means that NVCR stock's Price/Earning ratio is above 98% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this NVCR may be a overvalued for its sector.
The last closing price of NVCR's stock was USD 16.49.
The most recent market capitalization for NVCR is USD 1.81B.
Based on targets from 4 analysts, the average taret price for NVCR is projected at USD 34.36 over the next 12 months.
This means that NVCR's stock price may go up by +108.39% over the next 12 months.
We can't find any ETFs which contains Novocure Ltd's stock.
As per our most recent records Novocure Ltd has 1,488 Employees.
Novocure Ltd's registered address is Neuhofstrasse 21, Baar, Switzerland, 6340.
You can get more information about it from Novocure Ltd's website at https://www.novocure.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Novocure Ltd (NVCR) Stock
Based on ratings from 4 analysts Novocure Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NVCR's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for NVCR is USD 34.36 over the next 12 months. The maximum analyst target price is USD 46 while the minimum anlayst target price is USD 28.
NVCR stock's Price/Earning ratio is 1,480.87.
Our analysis grades NVCR stock's Price / Earning ratio at F. This means that NVCR stock's Price/Earning ratio is above 98% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this NVCR may be a overvalued for its sector.
The last closing price of NVCR's stock was USD 16.49.
The most recent market capitalization for NVCR is USD 1.81B.
Based on targets from 4 analysts, the average taret price for NVCR is projected at USD 34.36 over the next 12 months.
This means that NVCR's stock price may go up by +108.39% over the next 12 months.
We can't find any ETFs which contains Novocure Ltd's stock.
As per our most recent records Novocure Ltd has 1,488 Employees.
Novocure Ltd's registered address is Neuhofstrasse 21, Baar, Switzerland, 6340.
You can get more information about it from Novocure Ltd's website at https://www.novocure.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NVCR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
